Gabriel Mannis, MD, an Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine, discussed the TUSCANY trial of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy, as presented at the European Hematology Association 2025 Congress.
Dr. Gabriel Mannis Shares TUSCANY Trial Results of Tuspetinib Triplet in AML
By Melissa Badamo, Gabriel Mannis, MD - Last Updated: August 5, 2025Post Tags:EHA2025
Related Posts
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Naval Daver, MD reviews new targeted therapies transforming AML treatment in both young and older patient groups.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
A post-hoc analysis of long-term results in the AGILE trial adds to promising initial efficacy and safety results.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.